Here's my take:
1. Great result "60% reduction in death" which was "the pre-specified endpoint of cardiac death"
2. But "no reduction in non-fatal recurrent decompensated heart failure events, which was the trials primary endpoint"
Point 2 worried me until rereading, specifically "This suggests that rexlemestrocel-L reduces mortality by mechanisms that are distinct from those of existing drugs that reduce hospitalization rates but do not significantly impact cardiac mortality"
I interpret this to mean that there is no real benefit over existing medications in terms of recurring events, BUT a huge benefit of 60% of not dying from the disease.
If I have interpreted this correctly, then I'll take those odds any day.
- Forums
- ASX - By Stock
- Ann: Mesoblast Phase 3 Chronic Heart Failure Results
Here's my take:1. Great result "60% reduction in death" which...
-
- There are more pages in this discussion • 934 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.09 |
Change
-0.050(4.39%) |
Mkt cap ! $1.244B |
Open | High | Low | Value | Volume |
$1.14 | $1.17 | $1.07 | $8.385M | 7.489M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 8500 | $1.08 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.09 | 26954 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1 | 1.105 |
3 | 2124 | 1.080 |
6 | 147326 | 1.075 |
6 | 63157 | 1.070 |
7 | 43816 | 1.065 |
Price($) | Vol. | No. |
---|---|---|
1.040 | 3461 | 1 |
1.080 | 250 | 1 |
1.090 | 1428 | 2 |
1.095 | 40192 | 2 |
1.100 | 6192 | 2 |
Last trade - 16.10pm 19/06/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
HAR
HARANGA RESOURCES LIMITED.
Peter Batten, MD
Peter Batten
MD
Previous Video
Next Video
SPONSORED BY The Market Online